PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]

LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 loss-of-function carriers exhibit 15–30% lower circ...

Full description

Bibliographic Details
Main Authors: Brandon Ason, José W.A. van der Hoorn, Joyce Chan, Edward Lee, Elsbet J. Pieterman, Kathy Khanh Nguyen, Mei Di, Susan Shetterly, Jie Tang, Wen-Chen Yeh, Margrit Schwarz, J. Wouter Jukema, Rob Scott, Scott M. Wasserman, Hans M.G. Princen, Simon Jackson
Format: Article
Language:English
Published: Elsevier 2014-11-01
Series:Journal of Lipid Research
Subjects:
apolipoprotein E
anti-proprotein convertase subtilisin/kexin type 9 antibody
low density lipoprotein receptor
proprotein convertase subtilisin/kexin type 9
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520349889

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520349889

Similar Items